Amorphous Solid Dispersion Tablets Overcome Acalabrutinib pH Effect in Dogs

• Үндсэн зохиолчид: Deanna M. Mudie (Зохиогч), Aaron M. Stewart (Зохиогч), Jesus A. Rosales (Зохиогч), Nishant Biswas (Зохиогч), Molly S. Adam (Зохиогч), Adam Smith (Зохиогч), Christopher D. Craig (Зохиогч), Michael M. Morgen (Зохиогч), David T. Vodak (Зохиогч)
• Формат: Ном
• Хэвлэсэн: MDPI AG, 2021-04-01T00:00:00Z.
• Нөхцлүүд: article
• Онлайн хандалт: Connect to this object online.

Calquence^® (crystalline acalabrutinib), a commercially marketed tyrosine kinase inhibitor (TKI), exhibits significantly reduced oral exposure when taken with acid-reducing agents (ARAs) due to the low solubility of the weakly basic drug at elevated gastric pH. These drug-drug...